Trabectedin: an anticancer drug from the sea. (Q37594790)

21 August 2017

1 reference

title

Trabectedin: an anticancer drug from the sea. (English)

1 reference

21 August 2017

Kristen N Ganjoo

1

1 reference

21 August 2017

S R Patel

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

Expert Opinion on Pharmacotherapy

21 August 2017

published in

1 reference

21 August 2017

volume

10

1 reference

21 August 2017

issue

16

1 reference

21 August 2017

page(s)

2735-2743

1 reference

DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560903277236

In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903277236

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903277236

Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903277236

Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903277236

Hepatotoxicity and metabolism of trabectedin: a literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903277236

Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903277236

Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903277236

A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903277236

Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903277236

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903277236

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903277236

Myxoid liposarcoma. Experience with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903277236

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903277236

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903277236

A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903277236

A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903277236

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903277236

Extreme sensitivity to Yondelis® (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903277236

10.1517/14656560903277236

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference